Merna Armanious

TL;DR: The CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented and caution is suggested in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI.

TL;DR: In those who developed myocarditis related to an ICI, there was less myocardial injury and a lower risk of MACE among those who were administered the FV, and the rate of FV among ICI-related myCarditis cases was lower than controls on ICIs who did not develop myocardritis.

TL;DR: The adverse effects of RT on these organ systems are reviewed and risk reduction strategies that may effectively mitigate some of these adverse outcomes are discussed.

TL;DR: Recent advances in the field of cardio-oncology are discussed and a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitor, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies are provided.

TL;DR: There is strong evidence that ibrutinib itself is an independent risk factor for the development of incident AA, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blockers use, and aspirin use were independently associated with incident arrhythmias.